Develops novel immunotherapies and vaccine adjuvants to treat cancer, allergies, autoimmune diseases, and enhance vaccines.
Buy
Sign up to view historical trading trends and place an offer.
Sell
Understand share pricing, list anonymously, and benefit from transparent fees.
Overview
Inimmune is a clinical-stage biotech company focused on the discovery and development of novel immunotherapeutics for cancer, allergy, autoimmunity, and vaccines. The company’s pipeline includes clinical and pre-clinical assets such as Toll-like receptor agonists and next-generation vaccine adjuvants designed to harness the immune system to improve human health.
Buy
Sign up to view historical trading trends and place an offer.
Sell
Understand share pricing, list anonymously, and benefit from transparent fees.
Inimmune Management Team
Investors
Two Bear Capital Operations, LLC
Inimmune Valuations & Financials
View real-time NPM data on Inimmune stock including daily Inimmune stock price estimates, valuation history, and historical share price information. Access Inimmune financing rounds, secondary trade levels, cap table data, and private company comparable transactions. Use NPM's private company valuation database to track Inimmune pricing across six independent market signals. Looking for private company due diligence data sources on Inimmune? Get in touch to learn more.
Similar Companies
like Inimmune
Clipboard Health
Healthcare & Life Sciences
Uses technology to help nursing facilities get the right nurse at the right place at the right time.
Devoted Health
Healthcare & Life Sciences
Provides Medicare Advantage plans to improve older Americans' well-being with comprehensive and family-oriented care.
Capstan Medical
Healthcare & Life Sciences
Merges surgical robotics with catheter-based technology to repair and replace heart valves.
Loyal
Healthcare & Life Sciences
Develops therapies to treat the underlying causes of aging in dogs.
Q Bio
Healthcare & Life Sciences
Utilizes AI and continuous monitoring to provide personalized health insights for proactive well-being decisions.
Dragonfly Therapeutics
Healthcare & Life Sciences
Creates immune-based therapies designed to target and eliminate cancer cells.
FAQ
We have answers
Inimmune stock does not trade on public stock exchanges. Inimmune stock is considered a private security and you need to be an accredited investor to trade shares. To invest in Inimmune stock you can either buy shares directly through the company or work with a secondary trading marketplace like Nasdaq Private Market.
Learn more about the secondary market for private company shares on the investors page.
Inimmune Stock does not trade on public stock exchanges. In order to sell Inimmune shares you need to work directly with the company or with a secondary trading marketplace like Nasdaq Private Market. NPM has more than a decade of experience helping sell shares on the private market to our network of institutional investors.
Learn more about NPM services for selling privately held stock on the Employee Shareholders page.
Read more about how to sell private company stock on the private secondary market:
Inimmune does not have a publicly available stock price because it is privately held and not traded on public stock exchanges. Through the NPM Data and Intelligence database from Nasdaq Private Market, you can view Inimmune share price and other valuable private market data.
Read more about secondary market private company stock prices:
There is no ticker symbol for Inimmune stock because it is a private company. Private companies do not have ticker symbols like public companies, they are identified primarily by using the company ‘street’ name or legal name.
Nasdaq Private Market currently works with employees, ex-employees, and other company investors. In order to sell Inimmune stock you need to receive the company’s approval, which Nasdaq Private Market manages on your behalf.
Learn more about selling privately held stock on the Employee Shareholders page.
Read more about how to sell shares of a private company and eligibility for selling privately held stock:
Currently, Nasdaq Private Market only works with accredited entities and institutional investors to purchase private company stock. In order to invest in Inimmune stock, you need to be an accredited entity or institutional investor.
Learn more about the Nasdaq Private Market tool kit for investors on the Investor Trading page.
Once you buy or sell, stock share ownership must transfer before funds are wired. With Nasdaq Private Market, clients leverage our patent-pending Transfer and Settlement technology which streamlines and manages transfer activity from match to settlement.
To learn more about private company stock Transfer and Settlement, check out the Transfer and Settlement page.
Inimmune is a private company and has not had an IPO. There is currently no Inimmune IPO price. Get started to begin exploring the Nasdaq Private Market Data and Intelligence database and gain access to actionable data related to Inimmune IPO.
Learn more about Data and Intelligence private company stock data for institutional investors on the on the NPM Data and Intelligence Product Page.
